Oaktree Acquisition Corp. III Reports Q2 2026 Financial Results with Decline in Net Income

Oaktree Acquisition Corp. III Life Sciences reported its financial results for the second quarter of 2026, revealing a net income of $1.6 million for the three months ending June 30, 2026, down from $1.9 million in the same period of the previous year. The company generated interest income of $1.87 million from cash held in its trust account, which was offset by general and administrative expenses of $262,000. For the first half of 2026, net income totaled $3 million, compared to $3.5 million for the same period in 2025. The decline in net income is attributed to a decrease in interest earned on cash held in the trust account, which fell from $4.25 million in the first half of 2025 to $3.72 million in 2026.

As of June 30, 2026, Oaktree Acquisition Corp. III reported total assets of $206.5 million, a slight increase from $203.1 million at the end of 2025. The company’s cash balance outside of the trust account decreased to $1.18 million from $1.43 million at the end of the previous year. The trust account, which holds funds from the company’s initial public offering (IPO), increased to $205.3 million, reflecting the accretion of shares subject to possible redemption. The company’s liabilities also rose, with total current liabilities increasing to $1.73 million from $1.30 million at the end of 2025, primarily due to higher accounts payable and accrued expenses.

Oaktree Acquisition Corp. III has not yet identified a target for its initial business combination, which is a key focus for the company moving forward. The company has until October 25, 2026, to complete this business combination, and it may seek to extend this period with shareholder approval. The company continues to incur significant costs related to its acquisition plans and may need to raise additional capital to support its operations. As of the reporting date, the company had a working capital deficit of $469,905, indicating potential liquidity challenges.

In terms of operational metrics, the company has maintained its share structure, with 19.2 million Class A ordinary shares subject to possible redemption, reflecting a redemption value of $10.69 per share as of June 30, 2026. The company’s management has indicated that it will utilize the funds in the trust account primarily for the business combination, while cash held outside the trust account will be used for operational expenses and due diligence related to potential acquisition targets. The company’s future performance will depend on its ability to successfully identify and complete a business combination, as well as manage its operational costs effectively.